If the mortality rate for lung cancer is starting to fall of a cliff in part because of treatment effect—contributing to more than a third of the 2.2% decline in overall cancer mortality from 2016 to 2017—is that signal showing up on the radar of NCI’s Surveillance, Epidemiology, and End Results (SEER) Program?
Over the course of his first six months as NCI director, Anthony Letai has contended with federal budget turbulence, a record-setting government shutdown, and concerns about the flow of over research dollars.
